Discover and read the best of Twitter Threads about #GEA

Most recents (10)

😳🤯The hour flew by & none of us noticed!!

🙏🏽 @FogacciJoao for bringing the 🇧🇷 flair to #TumorBoardTuesday & #GastricCancer!!

🏆Remember your🆓CME

Look for Case Wrap Up🎀 04/28/22

📅Mark your calendar for 05/10/22 8pm ET when @FlavioRochaMD joins our #VirtualTumorBoard!!
Remember #TumorBoardTuesday education goes beyond Twitter - we offer 🆓 CME!!

Pick up your🏆#CME & NOW #MOC(‼️) by answering quick questions regarding a case similar to @FogacciJoao’s‼️

🔗ALL CME: integrityce.com/tbt

🔗 post rationale: bit.ly/3kcIXdv

🇧🇷🎁🇧🇷
#PostTest Q1️⃣ #CME #TumorBoardTuesday @MPishvaian

🤔Now that @FogacciJoao schooled us through updates on immunotherapy for #GastricCancer, how would you answer these 2 quick ❓

🧬 Which are potentially useful immunotherapy biomarkers in gastric cancer?
Read 21 tweets
1/9 #TumorBoardTuesday #PostTest Q1️⃣ #CME
Case🎀

@doctorC369 took us on a 🛣️through metastatic #GEA. Lots of pearls🦪 here. First: two ❓...then the wrap up!

🤔These biomarkers are actionable in advanced #EsophagoGastricCancer except…

👉🏽Posttest 🔗: bit.ly/3pKtAvs
2/9 #PostTest Q2️⃣ #CME #TumorBoardTuesday
👉🏽posttest🔗: bit.ly/3pKtAvs

ALL🥇CME🔗: integrityce.com/tbt

🤔 Addition of immunotherapy to chemotherapy in the 1st line Rx of advanced #EsophagoGastricCancer significantly improves PFS and OS PDL1 CPS>1%
3/9 #TumorBoardTuesday
Thursday Case🎀- 12.14.2021

Lots of take🏠messages- 2 TWEETS!
We discussed metastatic #GEA
✅Chemo + XRT needed to be used fast when facing obstruction- biomarkers can wait
📣✅REMEMBER- no 5-FU bolus‼️📣
Read 10 tweets
1/10 #TumorBoardTuesday
Thursday Case🎀
This week’s case: pt w #GEA not responding to FLOT w dMMR/MSI. Receives 3 doses of pembrolizumab->pCR!

💡Biomarker-based IO can be v successful, but better biomarkers needed‼️
➡️Explore wrap up below re: deploying IO in #UGI Image
2/10 #TumorBoardTuesday

👉👉 Don’t forget to pick up your 🆓 #CME credit by answering 2 quick ❓
Here is the post-test 🔗: bit.ly/3EgtZeE

ALL CME 🔗: integrityce.com/tbt Image
3/10 #TumorBoardTuesday
Thursday Case🎀

Take🏠messages:
We discussed #GastricCancer & immunotherapy (IO)
✅dMMR/MSI quite common- 8-22% of non-metastatic cases
✅Chemo less effective in dMMR disease, particularly 5-FU
✅High pCR with upfront IO
✅ctDNA may be a key biomarker
Read 13 tweets
@MPishvaian @TumorBoardTues @SalemGIOncDoc @YJanjigianMD @DocCatenacci @rachnatshroff @gabe_a_brooks @sonbol_bassam @JoeChaoMD @JohnEbbenMDPhD 2/13 #TumorBoardTuesday

Starts on FLOT. C2 c/b😴, neutropenia, LFT ⬆️.
Unplanned CT with🙅🏼‍♂️👎response, hard to separate mass from liver capsule (not metastatic).

MDC feels risk of R1 resection, but resectable. MMR testing, complete PMS2 & MLH1 loss
Read 15 tweets
1/12 #TumorBoardTuesday
Thurs 10/12/21 Case🎀
@ShaalanBeg @CancerCommons present a case of #PancreaticCancer that challenges us to🤔about cell signaling & mol bio➡️better outcomes.

📚We captured as much of the chat as we could:
twitter.com/i/events/14479…
#PanCan #KRAS #OncTwitter
2/12 #TumorBoardTuesday
Thurs Case🎀

Take🏠messages:
We discussed #PancreaticCancer & specific #KRAS mut
✅All KRAS muts aren’t ≠
✅KRAS G12R➡️⬆️autophagy
✅Autophagy= tumor can♻️cell components ➡️resistance
✅MEKi + autophagy inhib= strat for G12R
✅Repeat NGS on prog is🗝️!
3/12
#TumorBoardTuesday
Thursday Case🎀

👉👉 Don’t forget to pick up 🆓 #CME credit by answering 3 quick ❓
Here is the post-test 🔗: bit.ly/3Bzgply

ALL CME 🔗: integrityce.com/tbt
Read 15 tweets
#Deşifreiki
1-Hızlanıyoruz demiştik..
Hızlanınca, her yerden çatlama vs dağılma sesleri gelmeye başladı.
Önce yaşadıklarımıza inanamadık.
Başta doğal karşıladık.
Şimdi ise kendimizi sorguluyoruz.
Neler oluyor?
Çok acayip şeyler oluyor.
Burada önemli husus IRADE güçlü olacak.
2-Düşmanın ters psikolojik harekatına karşı şöyle söyleyelim.
Satranç ve savaş 6. Boyut kabilinde devam ediyor.
Ne bu toprakları teslim edeceğiz.
Ne devletimizi yıkmalarına , bölmelerine müsade edeceğiz.
Ne de Özümüzü kaybedeceğiz.
Satranç bir savaş oyunudur. Image
3-Görünürde Mars oluyoruz gibi ama , hep Mat ediyoruz.
Bilesiniz..
Sorun ise sizlerin FREKANS ayarlarınızı düzeltmeme..
Ve Bakar kör gibi davranışlarınızda..
Uyku halinden ayağa kalkmama..
Bu videoyu deprem öncesinden açıklamıştık. Image
Read 50 tweets
Ok...Honeymoon is over & now time to dissect the exciting new data presented @ #ESMO2020 for #GEC #KN590 #CM649 #ATTRCN4 #CM577
1st, thank you to all the pts who participated!
& 2nd, congrats to all the investigators involved!
It's fantastic to have +ve studies! Lets dive deep:
*Caution
I think the facts are accurate - please correct if not. (seeking the truth here)
My opinions are my opinions.
~15 min read (it's complicated)
No CME offered unfortunately 😒😉
Enjoy...
Background:
IO monotx effective in a subgroup of GEC pts in 1L+:
1. MSI-H
2. High PDL1 (cut-off at least CPS 10 22C3)
3. low tumor burden
4. PS0
5. Asian > Western pts
6. SCC > AC
7. GC > EGJ
Outside of above, most pts are better-served w chemo based on crossing #yinyang curves
Read 35 tweets
It will be important to look at the data closely, particularly by histology. Merck’s KEYTRUDA® (pembrolizumab) in Combination W Chemo Significantly Improved OS and PFS Compared W Chemo in 1L Metastatic Esophageal Cancer | Business Wire businesswire.com/news/home/2020…
We must recall that a ~500 pt study of the exact same regimen KN062 was recently statistically negative (HR0.85 p=0.046) in CPS>0 in adeno. Now the same regimen in KN590 N=749, in all-comers irrespective of PDL1 but including SCC, is +ve. What could be driving this difference?🤔
Let’s see the data: the make-up by histology (& PDL1!) & the benefit magnitude diffs (as might be expected) b/w them before we jump to conclusions on both CM577 and KN590, and also CM649. Let’s not make press releases drive the science! #esmo2020 is going to be a doozy for #GEA!!
Read 6 tweets
One of my labors of love. Appropriately online on Valentine’s Day! ❤️ Perioperative gFOLFIRINOX for #GEA with premptive iri dose reduction of hi risk UGT1A1 genotypes. ja.ma/2vCgd7T @UCCancerCenter @kturaga @SteveMaronMD with nice commentary @JoeChaoMD & @KlempnerSam.
The presentation of this poster at #ASCO2019, you can imagine, didn’t have any investors hovering around 😏.
Read 4 tweets
Around 3000 BCE in eastern #Europe, a Proto-Balto-Slavic #language started to diverge from #ProtoIndoEuropean.

The #Slavic branch of the #IndoEuropean #languages began about 2,000 years later when Proto-Slavic deviated from Proto-Balto-Slavic.

[Image: commons.wikimedia.org/wiki/File:Balt…] Source: The Indo-European L...
As the #Slavic-speaking area expanded during the first millennium CE (striped area on map), Proto-Slavic transitioned to Common Slavic. The #language underwent minor changes that occurred mostly uniformly across eastern #Europe, thereby maintaining mutual intelligibility. A map of eastern Europe sho...
Around the year 1000 CE #CommonSlavic began to split into the South, West, and East branches to which all modern #Slavic #languages belong.

Roughly 315m people speak a Slavic #language, mostly in Eastern #Europe (including the #Balkan peninsula), #CentralAsia, and #Siberia. A map of Europe highlightin...
Read 359 tweets

Related hashtags

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!